150 related articles for article (PubMed ID: 10463576)
1. Mosaic allelic insulin-like growth factor 2 expression patterns reveal a link between Wilms' tumorigenesis and epigenetic heterogeneity.
Ohlsson R; Cui H; He L; Pfeifer S; Malmikumpu H; Jiang S; Feinberg AP; Hedborg F
Cancer Res; 1999 Aug; 59(16):3889-92. PubMed ID: 10463576
[TBL] [Abstract][Full Text] [Related]
2. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor.
Vu TH; Chuyen NV; Li T; Hoffman AR
Cancer Res; 2003 Apr; 63(8):1900-5. PubMed ID: 12702581
[TBL] [Abstract][Full Text] [Related]
3. Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor.
Xu YQ; Grundy P; Polychronakos C
Oncogene; 1997 Mar; 14(9):1041-6. PubMed ID: 9070652
[TBL] [Abstract][Full Text] [Related]
4. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour.
Steenman MJ; Rainier S; Dobry CJ; Grundy P; Horon IL; Feinberg AP
Nat Genet; 1994 Jul; 7(3):433-9. PubMed ID: 7920665
[TBL] [Abstract][Full Text] [Related]
5. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour.
Ogawa O; Eccles MR; Szeto J; McNoe LA; Yun K; Maw MA; Smith PJ; Reeve AE
Nature; 1993 Apr; 362(6422):749-51. PubMed ID: 8097018
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor II and WT1 transcript localization in human fetal kidney and Wilms' tumor.
Yun K; Fidler AE; Eccles MR; Reeve AE
Cancer Res; 1993 Nov; 53(21):5166-71. PubMed ID: 8221652
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of H19, an imprinted and putative tumor repressor gene, is a preneoplastic event during Wilms' tumorigenesis.
Cui H; Hedborg F; He L; Nordenskjöld A; Sandstedt B; Pfeifer-Ohlsson S; Ohlsson R
Cancer Res; 1997 Oct; 57(20):4469-73. PubMed ID: 9377554
[TBL] [Abstract][Full Text] [Related]
8. Genomic imprinting and Wilms' tumor.
Moulton T; Chung WY; Yuan L; Hensle T; Waber P; Nisen P; Tycko B
Med Pediatr Oncol; 1996 Nov; 27(5):476-83. PubMed ID: 8827077
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor II messenger ribonucleic acid expression in Wilms tumor, nephrogenic rest, and kidney.
Yun K; Molenaar AJ; Fiedler AM; Mark AJ; Eccles MR; Becroft DM; Reeve AE
Lab Invest; 1993 Nov; 69(5):603-15. PubMed ID: 7504120
[TBL] [Abstract][Full Text] [Related]
10. Comparative reverse transcription-polymerase chain reaction and in situ hybridization analyses of human imprinted p57KIP2 and insulin-like growth factor 2 gene transcripts in fetal kidney and Wilms' tumors using archival tissue.
Soejima H; McLay J; Hatada I; Mukai T; Jinno Y; Niikawa N; Yun K
Lab Invest; 1998 Jan; 78(1):19-28. PubMed ID: 9461119
[TBL] [Abstract][Full Text] [Related]
11. Role of genomic imprinting in Wilms' tumour and overgrowth disorders.
Reeve AE
Med Pediatr Oncol; 1996 Nov; 27(5):470-5. PubMed ID: 8827076
[TBL] [Abstract][Full Text] [Related]
12. Constitutional relaxation of insulin-like growth factor II gene imprinting associated with Wilms' tumour and gigantism.
Ogawa O; Becroft DM; Morison IM; Eccles MR; Skeen JE; Mauger DC; Reeve AE
Nat Genet; 1993 Dec; 5(4):408-12. PubMed ID: 8298652
[TBL] [Abstract][Full Text] [Related]
13. Relaxation of IGF2 imprinting in Wilms tumours associated with specific changes in IGF2 methylation.
Sullivan MJ; Taniguchi T; Jhee A; Kerr N; Reeve AE
Oncogene; 1999 Dec; 18(52):7527-34. PubMed ID: 10602511
[TBL] [Abstract][Full Text] [Related]
14. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
15. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
Brown KW; Power F; Moore B; Charles AK; Malik KT
Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity.
Wang WH; Duan JX; Vu TH; Hoffman AR
J Biol Chem; 1996 Nov; 271(44):27863-70. PubMed ID: 8910385
[TBL] [Abstract][Full Text] [Related]
17. Paternally inherited submicroscopic duplication at 11p15.5 implicates insulin-like growth factor II in overgrowth and Wilms' tumorigenesis.
Algar EM; St Heaps L; Darmanian A; Dagar V; Prawitt D; Peters GB; Collins F
Cancer Res; 2007 Mar; 67(5):2360-5. PubMed ID: 17325026
[TBL] [Abstract][Full Text] [Related]
18. Monoallelic expression of the insulin-like growth factor-2 gene in ovarian cancer.
Yun K; Fukumoto M; Jinno Y
Am J Pathol; 1996 Apr; 148(4):1081-7. PubMed ID: 8644850
[TBL] [Abstract][Full Text] [Related]
19. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
20. Inherited and Sporadic Epimutations at the IGF2-H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumor.
Riccio A; Sparago A; Verde G; De Crescenzo A; Citro V; Cubellis MV; Ferrero GB; Silengo MC; Russo S; Larizza L; Cerrato F
Endocr Dev; 2009; 14():1-9. PubMed ID: 19293570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
